One-Year and 18-Month Outcomes in nAMD Patient Eyes Switched to Brolucizumab Alone versus to Brolucizumab Alternating with Other Anti-VEGF Agents.

Joseph M ConeyJasmyne E McCoySamriddhi Buxy SinhaNina SonbolianLujia ZhouThomas P HullShawn A LewisDavid G MillerMichael A NovakScott D PendergastHang PhamSean M PlattLlewelyn J RaoJerome P SchartmanLawrence J SingermanRichard DonkorMargaret FinkRyan ZubrickyHelene Karcher

Published in: Clinical ophthalmology (Auckland, N.Z.) (2023)

Treatment with either brolucizumab alone or brolucizumab alternating with another anti-VEGF can preserve vision, reduce CMT, and extend anti-VEGF injection intervals in patients with nAMD.

Keyphrases

vascular endothelial growth factor
endothelial cells
optical coherence tomography
case report
skeletal muscle
combination therapy
adipose tissue
replacement therapy